Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

C Göransson, N Vejlstrup, T Scheike… - International Journal of …, 2018 - Elsevier
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …
被引用次数：7 相关文章

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

C Göransson, N Vejlstrup… - … journal of cardiology, 2018 - pubmed.ncbi.nlm.nih.gov
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension Publikation …

C Goransson, N Vejlstrup, T Scheike, J Carlsen - ikm.ku.dk
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension Publikation …

C Goransson, N Vejlstrup, T Scheike, J Carlsen - core.ku.dk
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

C Göransson, N Vejlstrup… - International …, 2018 - internationaljournalofcardiology.com
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension.

C Göransson, N Vejlstrup, T Scheike… - International Journal of …, 2018 - europepmc.org
BACKGROUND: Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

C Göransson, N Vejlstrup, T Scheike… - International Journal of …, 2018 - research.regionh.dk
BACKGROUND: Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …

[引用][C] Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

International Journal of Cardiology, 2018 - core.ku.dk
Implications of cardiac variability with cardiovascular magnetic resonance imaging for
calculating trial sample size in pulmonary arterial hypertension - Fitmum: Fitness for good health …

Implications of cardiac variability with cardiovascular magnetic resonance imaging for calculating trial sample size in pulmonary arterial hypertension

C Goransson, N Vejlstrup, T Scheike, J Carlsen - ikm.ku.dk
Background Normally, morbidity precedes mortality in pulmonary arterial hypertension
(PAH) and is assessed with recognized surrogate measures of survival. Cardiovascular …